Thrombolysis with low dose tissue plasminogen activator.
作者信息
Doyle E, Britto J, Freeman J, Munro F, Morton N S
机构信息
Intensive Care Unit, Royal Hospital for Sick Children, Yorkhill, Glasgow.
出版信息
Arch Dis Child. 1992 Dec;67(12):1483-4. doi: 10.1136/adc.67.12.1483.
Abstract
Two cases of vena caval thrombosis in infants were successfully treated with low dose (0.01-0.05 mg/kg/hour) local infusions of tissue plasminogen activator after conventional anticoagulant treatment had been unsuccessful. This approach is useful for clots associated with indwelling intravascular catheters, and a low dose infusion of tissue plasminogen activator as a regional application is recommended to achieve clot lysis with minimal systemic effects.
摘要
相似文献
1
Thrombolysis with low dose tissue plasminogen activator.
Arch Dis Child. 1992 Dec;67(12):1483-4. doi: 10.1136/adc.67.12.1483.
2
Caval thrombolysis in neonates using low doses of recombinant human tissue-type plasminogen activator.
Anaesth Intensive Care. 1991 Feb;19(1):22-7. doi: 10.1177/0310057X9101900104.
3
Recombinant tissue plasminogen activator for neonatal and pediatric vascular thrombolytic therapy.重组组织型纤溶酶原激活剂用于新生儿和儿童血管溶栓治疗。
J Pediatr Surg. 1993 Oct;28(10):1264-8; discussion 1268-9. doi: 10.1016/s0022-3468(05)80310-0.
4
Recombinant tissue plasminogen activator.重组组织型纤溶酶原激活剂
Neonatal Netw. 1996 Sep;15(6):13-8.
5
[Successful lysis of a septic thrombosis of the superior vena cava using recombinant tissue-plasminogen activator].
Klin Padiatr. 1991 Sep-Oct;203(5):363-5. doi: 10.1055/s-2007-1025454.
6
Management of a large organized intraatrial catheter-tip thrombus in a child with acquired immunodeficiency syndrome using escalating tissue plasminogen activator infusions.使用递增剂量的组织纤溶酶原激活剂输注治疗一名患有获得性免疫缺陷综合征儿童的大型有组织的心房导管尖端血栓。
Pediatr Crit Care Med. 2005 Jan;6(1):79-82. doi: 10.1097/01.PCC.0000149681.08212.2E.
7
Thrombolytic therapy for the treatment of prosthetic heart valve thrombosis in pregnancy with low-dose, slow infusion of tissue-type plasminogen activator.低剂量、缓慢输注组织型纤溶酶原激活剂治疗妊娠合并人工心脏瓣膜血栓形成的溶栓治疗。
Circulation. 2013 Jul 30;128(5):532-40. doi: 10.1161/CIRCULATIONAHA.113.001145. Epub 2013 Jun 28.
8
Plasminogen-enriched pulse-spray thrombolysis with tPA: further developments.使用组织型纤溶酶原激活剂（tPA）的富含纤溶酶原脉冲喷雾溶栓：进一步进展。
J Vasc Interv Radiol. 2000 Nov-Dec;11(10):1353-62. doi: 10.1016/s1051-0443(07)61316-5.
9
Thrombolytic therapy with tissue plasminogen activator for superior vena cava thrombosis in an infant with sepsis.
Acta Paediatr. 2005 Feb;94(2):239-41. doi: 10.1111/j.1651-2227.2005.tb01899.x.
10
Treatment of superior vena cava thrombosis with recombinant tissue type plasminogen activator.
Chest. 1991 May;99(5):1298-301. doi: 10.1378/chest.99.5.1298.
引用本文的文献
1
Management of preterm infants with intracardiac thrombi: use of thrombolytic agents.患有心内血栓的早产儿的管理：溶栓剂的使用。
Paediatr Drugs. 2001;3(12):883-98. doi: 10.2165/00128072-200103120-00002.
2
Treatment of neonatal thrombus formation with recombinant tissue plasminogen activator: six years experience and review of the literature.重组组织型纤溶酶原激活剂治疗新生儿血栓形成：六年经验及文献综述
Arch Dis Child Fetal Neonatal Ed. 2001 Jul;85(1):F18-22. doi: 10.1136/fn.85.1.f18.
3
Pulmonary embolism in parenteral nutrition.肠外营养中的肺栓塞
Arch Dis Child. 1996 Feb;74(2):95-8. doi: 10.1136/adc.74.2.95.
4
Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction.阿替普酶。对其在急性心肌梗死以外血管疾病中的药理学及治疗应用的重新评估。
Drugs. 1995 Aug;50(2):289-316. doi: 10.2165/00003495-199550020-00007.
5
Tissue plasminogen activator (alteplase) treatment for femoral artery thrombosis after cardiac catheterisation in infants and children.组织型纤溶酶原激活剂（阿替普酶）治疗婴幼儿和儿童心导管插入术后股动脉血栓形成
Br Heart J. 1993 Oct;70(4):382-5. doi: 10.1136/hrt.70.4.382.
本文引用的文献
1
Thrombolytic therapy: current status (2).溶栓治疗：现状（2）
N Engl J Med. 1988 Jun 16;318(24):1585-95. doi: 10.1056/NEJM198806163182406.
2
Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator.
J Am Coll Cardiol. 1987 Sep;10(3):479-90. doi: 10.1016/s0735-1097(87)80188-2.
3
Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET).组织型纤溶酶原激活剂降低急性心肌梗死死亡率的试验。英-斯堪的纳维亚早期溶栓研究（ASSET）。
Lancet. 1988 Sep 3;2(8610):525-30. doi: 10.1016/s0140-6736(88)92656-6.
4
5
Caval thrombolysis in neonates using low doses of recombinant human tissue-type plasminogen activator.
Anaesth Intensive Care. 1991 Feb;19(1):22-7. doi: 10.1177/0310057X9101900104.
6
Tissue plasminogen activator for the treatment of thromboembolism in infants and children.组织型纤溶酶原激活剂用于治疗婴幼儿和儿童的血栓栓塞症。
J Pediatr. 1991 Mar;118(3):467-72. doi: 10.1016/s0022-3476(05)82170-5.
Zotero 插件